{"id":107370,"date":"2026-07-23T20:36:29","date_gmt":"2026-07-23T20:36:29","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/107370\/"},"modified":"2026-07-23T20:36:29","modified_gmt":"2026-07-23T20:36:29","slug":"bms-claims-pharmas-most-powerful-ai-supercomputer-how-it-stacks-up-to-lillys-and-roches","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/107370\/","title":{"rendered":"BMS claims pharma&#8217;s most powerful AI supercomputer. How it stacks up to Lilly&#8217;s and Roche&#8217;s."},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-35760\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/07\/AdobeStock_1975056363_Editorial_Use_Only-copy.webp\" alt=\"\" width=\"770\" height=\"500\"  \/>Bristol Myers Squibb said Monday it will deploy an <a href=\"https:\/\/news.bms.com\/news\/corporate-financial\/2026\/Bristol-Myers-Squibb-to-Build-the-Most-Powerful-AI-Factory-in-Life-Sciences-with-NVIDIA\/default.aspx\" rel=\"nofollow noopener\" target=\"_blank\">NVIDIA DGX SuperPOD<\/a>, a prepackaged supercomputing platform that NVIDIA sells as a single standard unit, combining multiple compute racks, high-speed networking and management software into one cluster. BMS describes it as the \u201cmost powerful and energy-efficient single-owned NVIDIA infrastructure in life sciences.\u201d<\/p>\n<p>That claim lands nine months after Eli Lilly announced <a href=\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lilly-partners-nvidia-build-industrys-most-powerful-ai\" rel=\"nofollow noopener\" target=\"_blank\">the industry\u2019s most powerful AI supercomputer<\/a> in October, and four months after Roche claimed <a href=\"https:\/\/www.roche.com\/media\/releases\/med-cor-2026-03-16\" rel=\"nofollow noopener\" target=\"_blank\">the industry\u2019s largest announced hybrid-cloud AI factory<\/a> in March.<\/p>\n<p>The build is an expansion rather than a first move. BMS has operated a DGX SuperPOD since 2024, and <a href=\"https:\/\/blogs.nvidia.com\/blog\/bristol-myers-squibb-building-life-science-industrys-most-advanced-ai-factory-on-nvidia-vera-rubin\/\" rel=\"nofollow noopener\" target=\"_blank\">NVIDIA\u2019s blog<\/a> says that system is now saturated. The two will be combined into a single environment accessible across BMS sites.<\/p>\n<p>What BMS bought<\/p>\n<p>Each rack in the new BMS cluster is a Vera Rubin NVL72 system, pairing 72 Rubin GPUs with 36 Vera CPUs so the rack operates as one machine rather than 72 separate ones. NVIDIA\u2019s blog puts the build at eight racks, or 576 GPUs, a figure absent from BMS\u2019s own release.<\/p>\n<p>Rubin is the generation that follows Blackwell, the chips behind both Lilly\u2019s and Roche\u2019s systems. For context, <a href=\"https:\/\/nvidianews.nvidia.com\/news\/nvidia-blackwell-platform-arrives-to-power-a-new-era-of-computing\" rel=\"nofollow noopener\" target=\"_blank\">at Blackwell\u2019s launch in March 2024<\/a>, NVIDIA said its GB200 NVL72 rack, which links 72 Blackwell GPUs into a single system, delivered up to 30 times the LLM inference performance of the same number of H100 GPUs and cut cost and energy consumption by up to 25 times.. NVIDIA said Rubin entered full production earlier this year, with <a href=\"https:\/\/investor.nvidia.com\/news\/press-release-details\/2026\/NVIDIA-Kicks-Off-the-Next-Generation-of-AI-With-Rubin--Six-New-Chips-One-Incredible-AI-Supercomputer\/default.aspx\" rel=\"nofollow noopener\" target=\"_blank\">partner availability in the second half of 2026<\/a>. NVIDIA <a href=\"https:\/\/investor.nvidia.com\/news\/press-release-details\/2026\/NVIDIA-Vera-Rubin-Opens-Agentic-AI-Frontier\/default.aspx\" rel=\"nofollow noopener\" target=\"_blank\">claims<\/a> roughly 10 times the inference throughput per watt of Blackwell at the rack level.\u00a0 Meanwhile, BMS cites up to 10 times the performance per megawatt over the system it is replacing. Both figures come from the vendor.<\/p>\n<p><a href=\"https:\/\/www.reuters.com\/legal\/litigation\/bristol-myers-buys-nvidias-latest-ai-computing-system-drug-research-2026-07-20\/?utm_source=chatgpt.com\" rel=\"nofollow noopener\" target=\"_blank\">Reuters reported BMS<\/a> as the first life-sciences company to buy a Rubin-based SuperPOD. That holds with one qualifier: NVIDIA said in January that Lilly\u2019s $1 billion co-innovation lab in South San Francisco would be built on the Vera Rubin architecture. Lilly named the architecture. BMS named a rack count.<\/p>\n<p>Three systems, three different disclosures<\/p>\n<p>The table below uses theoretical dense FP8 training performance, a common low-precision AI metric, for the two systems. These are peak reference-spec estimates. Measured performance on pharmaceutical workloads remains undisclosed. Roche\u2019s disclosure omits the Blackwell model and the network topology.\u00a0<\/p>\n<p>System<br \/>\nGPU hardware<br \/>\nPeak dense FP8 training*<br \/>\nGPU memory<br \/>\nDisclosed layout<\/p>\n<p>BMS, planned<br \/>\n576 Rubin GPUs<br \/>\n10.1 exaflops<br \/>\n166 TB<br \/>\nEight NVL72 racks, each with 72 GPUs and 36 Vera CPUs<\/p>\n<p>LillyPod, live<br \/>\n1,016 B300 Blackwell Ultra GPUs<br \/>\n4.6 exaflops<br \/>\n293 TB<br \/>\nEight GPUs per DGX B300 system, linked through a SuperPOD network<\/p>\n<p>Roche, operating<br \/>\n2,176 Blackwell GPUs on premises, more than 3,500 total<br \/>\nUnavailable from disclosure<br \/>\nUnavailable from disclosure<br \/>\nHybrid footprint across U.S. and European sites plus cloud, GPU model and topology undisclosed<\/p>\n<p>*The estimates multiply NVIDIA\u2019s current reference specifications across the disclosed hardware. Vera Rubin NVL72 provides 1.26 exaflops of dense FP8\/FP6 training performance per rack. <a href=\"https:\/\/www.nvidia.com\/en-us\/data-center\/dgx-b300\/\" rel=\"nofollow noopener\" target=\"_blank\">DGX B300<\/a> provides 72 petaflops of sparse FP8 performance per eight-GPU system, equal to 36 petaflops dense. NVIDIA labels the Rubin specifications preliminary, and separate B300 module documentation implies a higher dense FP8 rate than the DGX system figure, which would raise the Lilly estimate. Lilly\u2019s published figure of more than 9,000 petaflops aligns with NVIDIA\u2019s sparse FP8 specification across 127 DGX B300 systems; the table converts it to dense FP8 for comparison. Memory totals use 20.7 TB per Rubin rack and 288 GB per B300 GPU.<\/p>\n<p>Filed Under: <a href=\"https:\/\/www.drugdiscoverytrends.com\/category\/drug-discovery\/\" rel=\"category tag nofollow noopener\" target=\"_blank\">Drug Discovery<\/a><br \/>Tagged With: <a href=\"https:\/\/www.drugdiscoverytrends.com\/tag\/ai-infrastructure\/\" rel=\"tag nofollow noopener\" target=\"_blank\">AI infrastructure<\/a>, <a href=\"https:\/\/www.drugdiscoverytrends.com\/tag\/blackwell-ultra\/\" rel=\"tag nofollow noopener\" target=\"_blank\">Blackwell Ultra<\/a>, <a href=\"https:\/\/www.drugdiscoverytrends.com\/tag\/bms\/\" rel=\"tag nofollow noopener\" target=\"_blank\">BMS<\/a>, <a href=\"https:\/\/www.drugdiscoverytrends.com\/tag\/bristol-myers-squibb\/\" rel=\"tag nofollow noopener\" target=\"_blank\">Bristol-Myers Squibb<\/a>, <a href=\"https:\/\/www.drugdiscoverytrends.com\/tag\/dgx-superpod\/\" rel=\"tag nofollow noopener\" target=\"_blank\">DGX SuperPOD<\/a>, <a href=\"https:\/\/www.drugdiscoverytrends.com\/tag\/drug-discovery-ai\/\" rel=\"tag nofollow noopener\" target=\"_blank\">drug discovery AI<\/a>, <a href=\"https:\/\/www.drugdiscoverytrends.com\/tag\/eli-lilly\/\" rel=\"tag nofollow noopener\" target=\"_blank\">Eli Lilly<\/a>, <a href=\"https:\/\/www.drugdiscoverytrends.com\/tag\/life-sciences-computing\/\" rel=\"tag nofollow noopener\" target=\"_blank\">life sciences computing<\/a>, <a href=\"https:\/\/www.drugdiscoverytrends.com\/tag\/lillypod\/\" rel=\"tag nofollow noopener\" target=\"_blank\">LillyPod<\/a>, <a href=\"https:\/\/www.drugdiscoverytrends.com\/tag\/nvidia\/\" rel=\"tag nofollow noopener\" target=\"_blank\">NVIDIA<\/a>, <a href=\"https:\/\/www.drugdiscoverytrends.com\/tag\/pharma-supercomputer\/\" rel=\"tag nofollow noopener\" target=\"_blank\">pharma supercomputer<\/a>, <a href=\"https:\/\/www.drugdiscoverytrends.com\/tag\/pharmaceutical-ai\/\" rel=\"tag nofollow noopener\" target=\"_blank\">Pharmaceutical AI<\/a>, <a href=\"https:\/\/www.drugdiscoverytrends.com\/tag\/roche-ai-factory\/\" rel=\"tag nofollow noopener\" target=\"_blank\">Roche AI factory<\/a>, <a href=\"https:\/\/www.drugdiscoverytrends.com\/tag\/rubin-gpus\/\" rel=\"tag nofollow noopener\" target=\"_blank\">Rubin GPUs<\/a>, <a href=\"https:\/\/www.drugdiscoverytrends.com\/tag\/vera-rubin\/\" rel=\"tag nofollow noopener\" target=\"_blank\">Vera Rubin<\/a><br \/>\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"Bristol Myers Squibb said Monday it will deploy an NVIDIA DGX SuperPOD, a prepackaged supercomputing platform that NVIDIA&hellip;\n","protected":false},"author":2,"featured_media":107371,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[13727,52455,52456,24061,52457,52458,216,52459,29426,6007,52460,52461,134,52462,52463,52464],"class_list":["post-107370","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-ai-infrastructure","tag-blackwell-ultra","tag-bms","tag-bristol-myers-squibb","tag-dgx-superpod","tag-drug-discovery-ai","tag-eli-lilly","tag-life-sciences-computing","tag-lillypod","tag-nvidia","tag-pharma-supercomputer","tag-pharmaceutical-ai","tag-roche","tag-roche-ai-factory","tag-rubin-gpus","tag-vera-rubin"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116971214231445082","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/107370","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=107370"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/107370\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/107371"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=107370"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=107370"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=107370"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}